Semnur Pharmaceuticals, Inc. (SMNR)

Semnur Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-164.33	-160.42	-4.69	-3.26	-3.77
Stock-Based Compensation	143.83	142.44	0.66	0.84	0.87
Change in Accounts Payable	2.66	2.15	-	-	-0.78
Change in Other Net Operating Assets	9.71	9.97	-0.86	0.74	-0.37
Operating Cash Flow	-8.14	-5.87	-4.89	-1.68	-4.04
Long-Term Debt Issued	-	5.85	4.89	1.66	3.97
Net Debt Issued (Repaid)	7.37	5.85	4.89	1.66	3.97
Other Financing Activities	0.86	0.03	-	-	-
Financing Cash Flow	8.23	5.88	4.89	1.66	3.97
Net Cash Flow	0.1	0.01	-	-0.02	-0.07
Levered Free Cash Flow	52.84	54.2	-9.11	-0.45	-
Unlevered Free Cash Flow	52.84	54.2	-9.11	-0.45	-
Change in Working Capital	12.36	12.11	-0.86	0.74	-1.15

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 5, 2026

Data Sources Report a data error